22. Oct 2014 |
Fresenius Medical Care stands for dynamic growth in the years ahead. In addition to continued strong growth in the core business with dialysis products and the treatment of dialysis patients, the strategy sees considerable potential in the area of medical services relating to dialysis for the future. These include, for example, venous access management and the management of medication for kidney patients, as well as the laboratory and drug business. Up to 2020, the care coordination sector is to be expanded and its share of total turnover to rise from today’s 3 % to around 18 %.
With regard to the upcoming challenges for the company, the role of highly-qualified staff and the uniqueness of a particularly broadly-based position are of major significance. Above all, the interdisciplinary combination of science or engineering and commercial perspectives is a major advantage, offering diverse development possibilities in new fields.
On 10 October, 2014, Dr. Pierre Shephard, Project Manager at Fresenius Medical Care, was awarded a company scholarship for an in-service MBA programme at the Danube University Krems in Austria. The Danube University Krems is one of the leading providers of postgraduate courses in Austria and Europe and for many years has been a preferred partner of Fresenius Medical Care in the fostering of outstanding employees, particularly dedicated in their skills. Fresenius Medical Care has a long history of emphasising this form of staff development.
Dr. Shephard studied Biotechnology in England, followed by a doctorate in Biochemistry in Germany, and completed postgraduate studies in pharmaceuticals in Switzerland. He has been employed at Fresenius Medical Care since 2012 and looks after international products in the area of Renal Pharmaceuticals. The holder of a doctorate in Biochemistry is commencing his two-year MBA programme in Biotech & Pharmaceutical Management at the Danube University Krems in the coming weeks. This MBA course will also allow Dr. Shephard to deepen his knowledge of portfolio management and give him the opportunity to evaluate strategic projects both technically and financially.
Dominik Wehner, CEO of Region Europe, Middle East & Africa, presented Dr. Shephard with the scholarship certificate and emphasised the vital importance of both scientific and commercial perspectives for cooperation on diverse projects. Dr. Wolfgang Hofmann, Senior Vice President of Renal Pharma, congratulated the awardee with the words “the right choice”. With his capacity for high-powered implementation of projects as a highly-focussed team leader, Dr. Shepard fully meets the requirements for the programme. His direct supervisor, Dr. Uwe Wölk, Director Project Management Renal Pharma referred to Dr. Shephard’s particular skill: “Talent and experience are paired with a high degree of motivation“.